Total buying$00 buys
HALO
HALOZYME THERAPEUTICS, INC.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 09/20 to 10/20.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$7.17M16 sells
Net open-market−$7.17MBuying minus selling
Active insiders3Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 08, 2026
Open-market transaction mix · 16 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
| Oct 2026 | 0 | 16 | 2 | $0 | $7.17M | -$7.17M |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (3)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- PL-$567.7k
HALO transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
HALOHALOZYME THERAPEUTICS, INC. | Posard Matthew L.DIR | S · sale10b5-1 detectedSEC filing ↗ | -$11.0kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Posard Matthew L.DIR | S · sale10b5-1 detectedSEC filing ↗ | -$120kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Posard Matthew L.DIR | S · sale10b5-1 detectedSEC filing ↗ | -$357kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Posard Matthew L.DIR | S · sale10b5-1 detectedSEC filing ↗ | -$78.2kView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Recent filing activity
Most recent 4 transactions on this page · color = transaction codeFiling detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period24transactionstxns
- S · Open-market sells · dominant16 · 67%
- M · Option exercise6 · 25%
- A · Grants / awards2 · 8%
Activity by reported role
A joint filing can contribute to multiple rolesPRES18
Director6
Reported Holdings After
Separated by insider, security, and ownership type
Torley HelenCommon Stock · Direct
767,780Oct 08, 2026
Posard Matthew L.Common Stock · Direct
53,609Oct 01, 2026
Torley HelenOption to Purchase Common Stock · Direct
21,552Oct 08, 2026
Daly James MRestricted Stock Units · Direct
1,169Oct 01, 2026
Daly James MOption to Purchase Common Stock · Direct
1,775Oct 01, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 20 → Oct 20
LessMore
HALOZYME THERAPEUTICS, INC. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at HALOZYME THERAPEUTICS, INC.?
Torley Helen, Daly James M, Posard Matthew L..
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Torley Helen reported a sale on Oct 08, 2026 valued at $22.1k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $7,178,161.53. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.